Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901, its Claudin 18.2-targeted antibody-drug conjugate (ADC), triggering a $45 million milestone payment from AstraZeneca. The payment, received net of bank charges, represents progress under the 2023 global exclusive license agreement between KYM Biosciences (Keymed’s 70%-owned JV) and AstraZeneca, which included $63 million upfront and >$1.1 billion in potential milestones. The Phase III launch validates CMG901’s first-in-class potential in gastric and gastroesophageal junction (GEJ) cancer, where Claudin 18.2 expression drives significant unmet need.
HKG: 2162 shares expected to react positively to milestone validation and Phase III progress
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase III enrollment timelines, regulatory pathways, and milestone achievement for CMG901. Actual results may differ due to competitive dynamics with zolbetuximab, manufacturing scale-up challenges, and gastric cancer trial execution risks.-Fineline Info & Tech
